Article
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2023
Saltos Andreas N, Creelan Ben C, Tanvetyanon Tawee, Chiappori Alberto A, Antonia Scott J, Shafique Michael R, Ugrenovic-Petrovic Milijana, Sansil Samer, Neuger Anthony, Ozakinci Hilal, Boyle Theresa A, Kim Jongphil, Haura Eric B, Gray Jhanelle E
Abstract excerpt
BACKGROUND: Activating mutations in EGFR or KRAS are highly prevalent in NSCLC, share activation of the MAPK pathway and may be amenable to combination therapy to prevent negative feedback activation. METHODS: In this phase 1/1B trial, we tested the combination of binimetinib and erlotinib in patients with advanced NSCLC with at least 1 prior line of treatment (unless with activating EGFR mutation which could be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.